New partnership offers GreenScreen HC and BlueScreen HC via contract service
Research specialist Advancell has partnered with genotoxicity screening company Gentronix to offer a new screening service for the C&T industry.
The new partnership will offer GreenScreen HC and BlueScreen HC rapid human cell based assays to determine potential genotoxic liability in ingredients. The tests have been shown to be highly predictive in in vivo genotoxicity and genotoxic carcinogenesis, according to the two companies. The assays are also said to have a low compound requirement of 10mg or less and a fast turnaround time of 10 working days for analysis.
“The recent seventh amendment of the Cosmetics Directive and cessation of animal testing is focusing the industry to look for ever more accurate in vitro approaches to predicting likely in vivo genotoxic liabilities,” commented Dr Maria-Jesús Zurbano, R&D director of Advancell’s alternative testing unit. “The GreenScreen HC and BlueScreen HC assays are ideally suited to fulfil this role, and their ability to be deployed early in the discovery process means valuable information on perceived hazards can be acted upon before significant investment in product development.”